Article Text

Download PDFPDF
The Effect of Cyclooxygenase-2 Expression in Uterine Carcinosarcoma on Survival: A Reassessment Based on Mature Data
  1. Joseph Menczer, MD*,
  2. Letizia Schreiber, MD,,
  3. Esther Berger, PhD, and
  4. Tally Levy, MD*
  1. *Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, and
  2. Department of Pathology, E. Wolfson Medical Center, Holon, Israel; and
  3. Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel.
  1. Address correspondence and reprint requests to Joseph Menczer, MD, Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E. Wolfson Medical Center, Holon, Israel. E-mail:


Objective To reassess the effect cyclooxygenase-2 (COX-2) expression in carcinosarcoma on survival based on mature 5-year survival data.

Method A comparison of 5-year survival of 27 patients with carcinosarcoma according to the presence of COX-2 immunohistochemical staining and staining score was performed.

Results The 5-year survival of those with positive and negative COX-2 staining was statistically not different. However, there was a clear trend for more favorable 5-year survival in patients with a high staining score than in those with a low score, and the difference was of borderline significance (38.5% vs 7.1%; P = 0.06).

Conclusion In view of the role of COX-2 in carcinogenesis, our finding that COX-2 expression may confer a better survival in patients with carcinosarcoma is intriguing. Larger studies are indicated to elucidate the effect of COX-2 expression on survival in patients with carcinosarcoma because this may have therapeutic implications.

  • COX-2
  • Uterine carcinosarcoma
  • Survival

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • J. Menczer and L. Schreiber contributed equally.

  • The authors declare no conflicts of interest.